|
CFCF is pleased to announce that this E-Update is supported by Novartis Pharmaceuticals Corporation |
 Follow us on Twitter!
 Join us on Facebook!
Visit us on Navigating Cancer! |
(submitted 6/13/11)
CFCF is honored to present Survivor Stories. They reflect remarkable courage and determination. Thank you to our Survivors for sharing their courage and words of hope with other patients. |
|
Join Us for a Cure
Make a difference and get involved with CFCF! Unite, meet fellow members of the carcinoid community, and spread awareness at upcoming CFCF events! |
Give hope and a future to neuroendocrine tumor patients: donate to CFCF where 100% of all individual donations go to carcinoid and related neuroendocrine tumor research. CFCF is a 501(c)(3) organization-all contributions are tax-deductible. We want our donors to know that we are allocating their donations responsibly and wisely to achieve a carcinoid cure as quickly as possible.
To learn more, view CFCF's:
Audited Financial Statements
IRS Form 990
|
CFCF meets all 20 Wise Giving Alliance standards for charity accountability established by the Better Business Bureau. Click here to check out the CFCF Wise Giving Report. |
|
|
|
|
|
|
Further Research Progress from Johns Hopkins
Scientists from Johns Hopkins University have uncovered more information about the genetics of pancreatic neuroendocrine tumors!
In January 2011, CFCF-funded researchers found that mutations in two genes were correlated with the formation of pancreatic neuroendocrine cancers. Alan Meeker, Ph.D. and his team have pursued these mutations and now have data suggesting that both of these genes are also linked to why the ends of cellular DNA (known as "telomeres") lengthen in patients with cancer.
"If the correlation holds up, we could use [this information] as a method of determining a patient's prognosis in addition to developing treatments that target these genes," says Dr. Meeker.
A free abstract is available here from Science Express. Click here to read the press release acknowledging the Caring for Carcinoid Foundation's support.
|
|
New Global Study of Radiopeptide Therapy
Results from a single-center, phase II trial of radiopeptide therapy with Yttrium-90 (Y-90) were recently published in the Journal of Clinical Oncology and highlighted in Nature Reviews. 1,109 patients with a wide spectrum of metastatic neuroendocrine cancers came from 29 countries to participate in the study.
The authors found that response to Y-90 was associated with longer survival; however, this involved risk of severe, permanent renal toxicities. Therefore, the authors state more research is necessary to refine the clinical use of Y-90.
In addition, their data on both tumor and kidney uptake suggest that somatostatin receptor imaging may become a valuable predictive imaging tool. For more information, see the free abstract here.
Any patients considering this or any other potential treatment should consult with a physician well-versed in treating neuroendocrine tumor patients. Please consult CFCF's Doctor Database or call 617-948-2514 for help finding an experienced clinician. |
|
Help Shape Our Stanford Education Event
 Get ready for our second Neuroendocrine Tumor Patient Education Conference at Stanford University on September 10. This event will feature numerous opportunities for attendees and presenters to interact with each other through presentations, poster sessions, meals, and panels. Patients and caregivers, what would you like to hear our Patient Panel discuss? Vote here! If you have any other questions or suggestions, feel free to send them to info@caringforcarcinoid.org or call us at 617-948-2514. Registration is now open. We look forward to seeing you in September! |
|
Make a Splash - Support Cancer Research!
 Celebrate the beautiful summer weather by supporting Team CFCF in Swim Across America's Boston Harbor Swim on Friday, July 15.
Join Executive Director Lauren Erb and the rest of the team as we plunge into the harbor to raise funds for life-saving neuroendocrine cancer research. Support the Team today!
If you are interested in joining us next year or participating in other swim events, please e-mail Ellen Eisner or call 617-948-2514.
|
|
|
|
|
